Literature DB >> 30218190

Long-term renal follow-up of children treated with cisplatin, carboplatin, or ifosfamide: a pilot study.

Kelly R McMahon1,2, Maya Harel-Sterling3, Michael Pizzi1, Louis Huynh4, Erin Hessey5, Michael Zappitelli6,7.   

Abstract

BACKGROUND: Childhood cancer survivors treated with cisplatin, ifosfamide, or carboplatin are at risk for late kidney and blood pressure (BP) abnormalities. Few studies have comprehensively evaluated kidney outcomes and 24-h ambulatory BP monitoring (ABPM) in this population. We aimed to describe chemotherapy-associated acute kidney injury (AKI) and late kidney outcomes using standardized definitions.
METHODS: This was a single-center longitudinal pilot study of 23 children who participated in a previous study during cisplatin, carboplatin, or ifosfamide treatment. Medical charts were reviewed retrospectively. Available patients were approached for a study visit for blood and urine collection, BP measurement, and ABPM. AKI is defined by serum creatinine (SCr) rise (Kidney Disease: Improving Global Outcomes definition [SCr-AKI]). Electrolyte-AKI is defined by hypokalemia, hypophosphatemia, or hypomagnesemia. Chronic kidney disease (CKD) is defined by estimated glomerular filtration rate < 90 mL/min/1.73 m2, albuminuria, or proteinuria. Electrolyte-CKD is defined by low serum electrolyte concentration or electrolyte supplementation.
RESULTS: Median age at chemotherapy start was 8.3 years; 9/23 (39%) were boys. Fourteen out of 23 (61%) patients had SCr-AKI during therapy; all developed electrolyte-AKI. Median 5.7 years post-chemotherapy, 7/22 (32%) had CKD, 11/23 (48%) had electrolyte-CKD, and 2/20 (10%) had hypertension. Fifteen out of 23 patients (65%) had either CKD, electrolyte-CKD, or hypertension. In ten patients available for a study visit (median 4.9 years post-chemotherapy), 1/10 (10%) had hypertension by ABPM; none had masked or white coat hypertension. All ten had at least one kidney abnormality (CKD, electrolyte-CKD, office pre-hypertension, or abnormal ABPM).
CONCLUSIONS: Using standardized outcome definitions, children treated with cisplatin, carboplatin, or ifosfamide have a high prevalence of late kidney abnormalities. Research must elucidate best practice for post-cancer treatment follow-up and kidney complication treatment.

Entities:  

Keywords:  Acute kidney injury; Chemotherapy; Chronic kidney disease; Hypertension; Pediatric

Mesh:

Substances:

Year:  2018        PMID: 30218190     DOI: 10.1007/s00467-018-3976-5

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  26 in total

1.  The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents.

Authors: 
Journal:  Pediatrics       Date:  2004-08       Impact factor: 7.124

2.  Recommendations for the use of home (self) and ambulatory blood pressure monitoring. American Society of Hypertension Ad Hoc Panel.

Authors:  T Pickering
Journal:  Am J Hypertens       Date:  1996-01       Impact factor: 2.689

3.  Ambulatory blood pressure nondipping status in salt-sensitive and salt-resistant black adolescents.

Authors:  D K Wilson; D A Sica; S B Miller
Journal:  Am J Hypertens       Date:  1999-02       Impact factor: 2.689

4.  Renal dysfunction and elevated blood pressure in long-term childhood cancer survivors.

Authors:  Sebastiaan L Knijnenburg; Monique W Jaspers; Helena J van der Pal; Antoinette Y Schouten-van Meeteren; Antonia H Bouts; Jan A Lieverst; Arend Bökenkamp; Caro C E Koning; Foppe Oldenburger; James C H Wilde; Flora E van Leeuwen; Huib N Caron; Leontien C Kremer
Journal:  Clin J Am Soc Nephrol       Date:  2012-07-19       Impact factor: 8.237

5.  Survivors of childhood cancer in the United States: prevalence and burden of morbidity.

Authors:  Siobhan M Phillips; Lynne S Padgett; Wendy M Leisenring; Kayla K Stratton; Ken Bishop; Kevin R Krull; Catherine M Alfano; Todd M Gibson; Janet S de Moor; Danielle Blanch Hartigan; Gregory T Armstrong; Leslie L Robison; Julia H Rowland; Kevin C Oeffinger; Angela B Mariotto
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2015-04       Impact factor: 4.254

6.  Recommendations for blood pressure measurement in humans and experimental animals: part 1: blood pressure measurement in humans: a statement for professionals from the Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research.

Authors:  Thomas G Pickering; John E Hall; Lawrence J Appel; Bonita E Falkner; John Graves; Martha N Hill; Daniel W Jones; Theodore Kurtz; Sheldon G Sheps; Edward J Roccella
Journal:  Circulation       Date:  2005-02-08       Impact factor: 29.690

7.  Persistent nephrotoxicity during 10-year follow-up after cisplatin or carboplatin treatment in childhood: relevance of age and dose as risk factors.

Authors:  Roderick Skinner; Annie Parry; Lisa Price; Michael Cole; Alan W Craft; Andrew D J Pearson
Journal:  Eur J Cancer       Date:  2009-10-21       Impact factor: 9.162

Review 8.  Early and late renal adverse effects after potentially nephrotoxic treatment for childhood cancer.

Authors:  Sebastiaan L Knijnenburg; Renée L Mulder; Antoinette Y N Schouten-Van Meeteren; Arend Bökenkamp; Hester Blufpand; Eline van Dulmen-den Broeder; Margreet A Veening; Leontien C M Kremer; Monique W M Jaspers
Journal:  Cochrane Database Syst Rev       Date:  2013-10-08

9.  A new equation to estimate glomerular filtration rate.

Authors:  Andrew S Levey; Lesley A Stevens; Christopher H Schmid; Yaping Lucy Zhang; Alejandro F Castro; Harold I Feldman; John W Kusek; Paul Eggers; Frederick Van Lente; Tom Greene; Josef Coresh
Journal:  Ann Intern Med       Date:  2009-05-05       Impact factor: 25.391

10.  Risk factors for nephrotoxicity after ifosfamide treatment in children: a UKCCSG Late Effects Group study. United Kingdom Children's Cancer Study Group.

Authors:  R Skinner; S J Cotterill; M C Stevens
Journal:  Br J Cancer       Date:  2000-05       Impact factor: 7.640

View more
  13 in total

1.  Cisplatin-induced nephrotoxicity in childhood cancer: comparison between two countries.

Authors:  Anke H Maitland-van der Zee; Bruce C Carleton; Zulfan Zazuli; Catharina J P Op 't Hoog; Susanne J H Vijverberg; Rosalinde Masereeuw; Shahrad Rod Rassekh; Mara Medeiros; Rodolfo Rivas-Ruiz
Journal:  Pediatr Nephrol       Date:  2022-06-24       Impact factor: 3.714

2.  Urine Neutrophil Gelatinase-Associated Lipocalin and Kidney Injury Molecule-1 to Detect Pediatric Cisplatin-Associated Acute Kidney Injury.

Authors:  Kelly R McMahon; Hayton Chui; Shahrad Rod Rassekh; Kirk R Schultz; Tom D Blydt-Hansen; Cherry Mammen; Maury Pinsk; Geoffrey D E Cuvelier; Bruce C Carleton; Ross T Tsuyuki; Colin J D Ross; Prasad Devarajan; Louis Huynh; Mariya Yordanova; Frédérik Crépeau-Hubert; Stella Wang; Vedran Cockovski; Ana Palijan; Michael Zappitelli
Journal:  Kidney360       Date:  2021-11-03

3.  Pharmacological inhibitors of autophagy have opposite effects in acute and chronic cisplatin-induced kidney injury.

Authors:  Sophia M Sears; Joanna L Feng; Andrew Orwick; Alexis A Vega; Austin M Krueger; Parag P Shah; Mark A Doll; Levi J Beverly; Leah J Siskind
Journal:  Am J Physiol Renal Physiol       Date:  2022-07-07

4.  Pediatric Onco-Nephrology: Time to Spread the Word-Part II: Long-Term Kidney Outcomes in Survivors of Childhood Malignancy and Malignancy after Kidney Transplant.

Authors:  Arwa Nada; Jennifer G Jetton
Journal:  Pediatr Nephrol       Date:  2021-09-06       Impact factor: 3.651

5.  Late-onset kidney failure in survivors of childhood cancer: a report from the Childhood Cancer Survivor Study.

Authors:  Bryan V Dieffenbach; Qi Liu; Andrew J Murphy; Deborah R Stein; Natalie Wu; Arin L Madenci; Wendy M Leisenring; Nina S Kadan-Lottick; Emily R Christison-Lagay; Robert E Goldsby; Rebecca M Howell; Susan A Smith; Kevin C Oeffinger; Yutaka Yasui; Gregory T Armstrong; Christopher B Weldon; Eric J Chow; Brent R Weil
Journal:  Eur J Cancer       Date:  2021-08-11       Impact factor: 10.002

6.  Capillary rarefaction is more closely associated with CKD progression after cisplatin, rhabdomyolysis, and ischemia-reperfusion-induced AKI than renal fibrosis.

Authors:  Anna Menshikh; Lauren Scarfe; Rachel Delgado; Charlene Finney; Yuantee Zhu; Haichun Yang; Mark P de Caestecker
Journal:  Am J Physiol Renal Physiol       Date:  2019-09-11

7.  Childhood Cancer and the Risk of ESKD.

Authors:  Ronit Calderon-Margalit; Oren Pleniceanu; Dorit Tzur; Michal Stern-Zimmer; Arnon Afek; Tomer Erlich; Guy Verhovsky; Lital Keinan-Boker; Karl Skorecki; Gilad Twig; Asaf Vivante
Journal:  J Am Soc Nephrol       Date:  2020-11-12       Impact factor: 10.121

Review 8.  Childhood risk factors for adulthood chronic kidney disease.

Authors:  Michal Stern-Zimmer; Ronit Calderon-Margalit; Karl Skorecki; Asaf Vivante
Journal:  Pediatr Nephrol       Date:  2020-06-04       Impact factor: 3.714

9.  Dosing Recommendations for Pediatric Patients With Renal Impairment.

Authors:  Amer Al-Khouja; Kyunghun Park; Daijha J C Anderson; Caitlyn Young; Jian Wang; Shiew Mei Huang; Mona Khurana; Gilbert J Burckart
Journal:  J Clin Pharmacol       Date:  2020-06-15       Impact factor: 3.126

Review 10.  An overview of diagnosis and management of drug-induced hypomagnesemia.

Authors:  George Liamis; Ewout J Hoorn; Matilda Florentin; Haralampos Milionis
Journal:  Pharmacol Res Perspect       Date:  2021-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.